Description

Listing of 17,12,79,553 equity shares of Biocon Limited issued at Rs. 405.78 on preferential basis pursuant to share swap, effective January 12, 2026.

Summary

BSE has announced the listing of 17,12,79,553 new equity shares of Biocon Limited (Scrip Code: 532523) effective from Monday, January 12, 2026. These shares were issued to non-promoters on a preferential basis pursuant to a share swap arrangement at an issue price of Rs. 405.78 per share (face value Rs. 5 plus premium of Rs. 400.78). The newly listed shares will rank pari-passu with existing equity shares.

Key Points

  • 17,12,79,553 equity shares of Rs. 5/- each issued at premium of Rs. 400.78/-
  • Issued to non-promoters on preferential basis pursuant to share swap
  • Trading commences on BSE from Monday, January 12, 2026
  • Shares rank pari-passu with existing equity shares
  • Distinctive Numbers: 1336963636 to 1508243188
  • Date of Allotment: January 5, 2026
  • ISIN: INE376G01013
  • Total lock-in period: 6 months from allotment date

Regulatory Changes

No regulatory changes. This is a standard listing announcement for preferential allotment.

Compliance Requirements

  • Trading members are informed to note the new securities for trading purposes
  • Lock-in restrictions apply to all 17,12,79,553 shares until July 13, 2026
  • Shares cannot be transferred or sold before lock-in expiry date

Important Dates

  • Allotment Date: January 5, 2026
  • Trading Commencement: January 12, 2026
  • Lock-in Expires: July 13, 2026

Impact Assessment

Market Impact: The addition of 171.28 million shares represents a significant increase in Biocon’s equity capital, though the immediate market impact is limited due to the 6-month lock-in period. The shares are issued at a substantial premium (Rs. 400.78), indicating the transaction valued Biocon at the issue price level.

Liquidity Impact: Post lock-in expiry on July 13, 2026, these shares will become tradable, potentially increasing free float and liquidity in Biocon stock.

Ownership Impact: The preferential allotment to non-promoters through share swap suggests a strategic transaction, likely involving acquisition or merger activity. The substantial number of shares issued will dilute existing shareholders’ holdings.

Impact Justification

Material listing of significant number of equity shares (171.28 million) on preferential basis with lock-in period, impacting Biocon's capital structure